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Background. The detection of latent tuberculosis (TB) is essential for TB control, but T-cell assay might be inﬂuenced by degree
of immunosuppression. The relationship between immunocompetence and interferon (IFN)-γ response in QuantiFERON-TB
Gold (QFT) is uncertain, especially in HIV-negative populations. Methods and Results. QFT has been performed for healthy
subjects and TB suspected patients. Of 3017 patients, 727 were diagnosed as pulmonary TB by culture. The absolute number
of blood lymphocyte in TB patients was signiﬁcantly associated with QFT. Deﬁnitive TB patients were divided into eight groups
according to lymphocyte counts. For each subgroup, receiver operating characteristic curve analysis was conducted from 357
healthy control subjects. The optimal cut-oﬀ for the patient group with adequate lymphocyte counts was found, but this was
reduced for lymphocytopenia. Conclusions. The lymphocyte count was positively associated with QFT. Positive criteria should be
calibrated in consideration of cell-mediated immunocompetence and risk of progression to active TB.
1.Introduction
Treatment of persons with latent tuberculosis infection
(LTBI) is essential to prevent the development of active
tuberculosis (TB). Although the greatest risk of TB disease
is traditionally associated with recent exposures, immuno-
compromised hosts represent a setting in which reactivation
of TB from more remote exposures is a concern. The US
Centers for Disease Control and Prevention (CDC) recom-
mends targeted testing for LTBI in speciﬁc at-risk groups,
includingimmunocompromisedindividualswithHIVinfec-
tion, receiving immunosuppressive therapy, chronic renal
failure, solid organ transplant, silicosis, cancer of the head or
neck and lung, malnutrition, and diabetes [1]. The targeted
treatment of LTBI in these populations is also central to TB
control at the public health level [1, 2].
Until recently, tuberculin skin testing (TST) was the only
test for the detection of LTBI, but now in vitro T-cell-based
IFN-γ assays that are highly speciﬁc for mycobacterium
tuberculosis (Mtb) have been developed as alternative
diagnostic test [3]. In contrast to TST, T-cell assays are
unaffected by previous BCG vaccination and infection
with most environmental nontuberculous mycobacteria [4].
QuantiFERON-TB Gold in tube (QFT-IT) (Cellestis, Car-
negie, Australia) and T-SPOT. TB (Oxford Immunotec,
Oxford, UK) are two types of commercially available T-
cellassay.QuantiFERON-TBGold(QFT;secondgeneration)
and QFT-IT (third generation) are whole blood assays based
on enzyme-linked immunosorbent assay, whereas the T-
SPOT. TB uses peripheral blood mononuclear cells for
antigen stimulation in an enzyme-linked immunospot assay.
Although there is no gold standard for LTBI diagnosis, when
surrogate markers of recent exposure to Mtb are used, T-cell
assays have been shown in many studies to be as good if not
better than the TST in a contact investigation [5, 6]. CDC2 Tuberculosis Research and Treatment
guidelines recommend the single use of QFT in place of the
TST for all circumstances in which the TST is used [7].
The TST is well known to have diminished sensitivity
in the setting of immunocompromised hosts. False-negative
results in TST were reported, for example, in elderly people
and in malnutrition [8, 9]. A recent study suggested that
T-cell assays identiﬁed more immunocompromised patients
with LTBI than did the TST [10]. Because these new T-cell
assays rely on measuring speciﬁc acquired cell-mediated
immuneresponses,anyimmunomodulatingfactorsaﬀecting
cellular immunity in vivo may impact on the test perfor-
mance in vitro [11]. However, the correlation between the
degree of immunocompetence and speciﬁc IFN-γ responses
is not clear. Furthermore, most studies have analysed data
from T-cell assays as dichotomous results using a single
cutoﬀ value, and little work has been done on validation
of thresholds in consideration of immunological diversity.
T h e r ei se p i d e m i o l o g i c a le v i d e n c et os u p p o r tt h eu s eo f
risk-stratiﬁed cutoﬀ values, as in the interpretation of TST
[1]. However, no such data exist presently for T-cell assays.
We hypothesized that the appropriate positive cutoﬀ value
in QFT for diagnosing LTBI would be diﬀerent in immuno-
competent populations and immunosuppressed hosts with
impairedcell-mediatedimmunity.Theobjectiveofthisstudy
is therefore to identify immune-related clinical indicators
associated with the degree of antigen-speciﬁc IFN-γ produc-
tion using a large immunologically unselected population
withobviousTBinfection.Secondly,basedontheseﬁndings,
we revised the threshold values of QFT for populations with
diﬀerent immune status in clinical practice.
2. Methods
2.1. Participants. From January 2006 to October 2008, new
patients and healthy subjects in our hospital verbally con-
senting to the study were consecutively enrolled after the
research protocol was approved by the institutional review
board of National Tokyo Hospital (IRB). QFT assay is now
approved by national medical insurance in Japan and should
be indicated to diagnose TB infection in clinical practice.
IRB approves a verbal informed consent for QFT assay.
QFT was prescribed by hospital physicians for inpatients
and outpatients in any ward, without any inﬂuence of the
investigators. For all patients recruited into the study, infor-
mation on their previous medical history, clinical symptoms
and signs, and radiological and microbiological data were
collected at the time of enrollment. Bronchial lavage ﬂuid
samples obtained by bronchoﬁberscopy were collected and
cultured for mycobacteria when it was judged necessary.
Clinicians did not take QFT results into account for their
ﬁnal diagnosis. Several routine laboratory tests for clinical
diagnosis were simultaneously performed. We also routinely
performed QFT on healthy employees at the start of their
employment. We collected information on history of prior
TB, previous working in any healthcare settings or recent
exposuretoapatientwithactiveTBandotherTBriskfactors
such as taking immunosuppressive drugs.
2.2. Whole Blood QuantiFERON-TB Gold Assay. The test
was performed according to the manufacturer’s instructions.
The interpretation of the results was performed accord-
ing to the guidelines proposed by CDC [7]. Previously
we evaluated that this test would have 74% sensitivity
in all patients including HIV-negative immunosuppressive
patients [12]. However, it was increased to 88% in patients
with peripheral lymphocyte counts ≥1000cells/mm3.T w o
specialized technicians running the test in our hospital were
completely blinded to individual clinical information and
ﬁnal diagnosis.
2.3. Statistical Analysis. Associations between antigen-spe-
cific IFN-γ production in the QFT assay and several clin-
ical characteristics were examined by ﬁtting a linear model.
Regression diagnostic exercises included inspection of resid-
ual distributions (quantile-quantile and normal-probability
plots, residuals-versus-ﬁtted plots), nonlinearity in the func-
tional relationship with predictors (augmented component-
versus-residual plots), and examination for collinearity
(variance inﬂation factor). Predictions made from the ﬁtted
model were expressed in the original metric with the aid
of Duan’s smearing estimation. Assay results were sub-
jected to maximum-likelihood logistic regression against the
categorized subpopulations. Pairwise diﬀerences in logistic
regression coeﬃcients were compared at a Type I error rate
of 0.05, adjusted for multiple comparisons by the Bonferroni
method. Pairwise comparisons were made between areas
under the receiver operating characteristic (ROC) curve
(AUROC) for the categorized groups. Adjustment for mul-
tiple comparisons was made using the Dunn-Sida’k method.
P values <. 05wereconsideredsigniﬁcant.Statisticalanalysis
was conducted with Stata, Release 10.1 and 11 (StataCorp
LLP, College Station, Texas, U.S.A.), and GraphPad Prism 5
(GraphPad software, San Diego, California).
3. Results
3.1. Characteristics of the Patients. A total of 3762 subjects
underwent initial QFT testing. As shown in Figure 1,o f
the 3017 TB suspects, 727 patients were ﬁnally diagnosed
as having deﬁnite active pulmonary TB based on the
microbiological detection of Mtb from sputum or bronchial
lavage ﬂuid obtained using bronchoﬁberscopy. We excluded
patients with probable TB in which no bacteriological evi-
dence was obtained, persons with recent exposure to smear-
positive TB patients, and those who had been receiving of
antituberculous treatment for more than 14 days at the time
of testing. Characteristics of patients with active TB are
shown in Table 1. More males than females participated in
the study, and most of the study participants were Japanese.
Themajority(98.9%)wasHIVseronegative.Positivesputum
smears were found in 552 of 727 patients (75.9%). Clinical
immunomodulatoryfactorspertainingtotheTBpatientsare
also shown in Table 1. Patients could have multiple factors at
the same time.
3.2. Clinical Predictors Related to the Speciﬁc IFN-γ
ResponseinTBPatients. AssociationsbetweenspeciﬁcIFN-γTuberculosis Research and Treatment 3
Patients and healthy subjects
n = 3762
Patients with suspected TB
n = 3017
Healthy subjects
n = 745
Non-TB diseases
n = 2112
Probable TB, contacts and clinically indeterminate
diagnosis
n = 169
Microbiologically conﬁrmed pulmonary TB
n = 736
Receiving over 14 days of
antituberculous treatment
n = 9
Study population with active pulmonary TB
n = 727
Medical history of
tuberculosis or contact with
active TB patients and
history of previous working
in any healthcare setting,
Immunosuppressive
condition
n = 388
Healthy subjects with low risk for TB infection
n = 357
Figure 1: Study participants recruitment proﬁle. TB: tuberculosis.
production in unselected TB patients and several patient
characteristics were examined by ﬁtting to a linear model.
For this, the response variable was the maximum IFN-γ
after stimulating with ESAT-6 and CFP-10, logarithmically
transformed in order to make the distribution of the mod-
el residuals approximate more closely to normal and ho-
moscedastic. The following patient characteristics were used
as predictors of antigen-stimulated IFN-γ production: age,
absolute counts of lymphocytes, monocytes, neutrophils and
eosinophils, mitogen-stimulated IFN-γ production (positive
control) and nil (background) negative control IFN-γ,a n d
various clinical laboratory test results that might relate to
immunocompetence and general condition (serum albumin
and blood hemoglobin concentrations), inﬂammatory status
(C-reactive protein level; CRP), serum creatinine concentra-
tion, and serum liver enzyme activity levels. None of the
predictors were transformed. The values for certain clinical
laboratory test results were scaled as needed in order to
bring them into similar numerical domains; in practice,
this meant that leukogram-related regression coeﬃcients are
given in units of thousands of formed elements cells/mm3.
Three values were missing for albumin, and three for CRP.
The total observations available for regression were therefore
721. Regression coeﬃcients, their standard errors, P values,
and 95% conﬁdence intervals are presented in Table 2.B o t h
backgroundandmitogen-backgroundcontrolconditionsare
positively associated with antigen-speciﬁc IFN-γ production
(P<. 0005 and P = .006, resp.). Lymphocyte count is like-
wise positively associated with the test kit response (P<
.0005). Neutrophil count is negatively associated with spe-
ciﬁc response (P<. 0005).
3.3. QFT Results in Lymphocyte-Stratiﬁed TB Populations.
Next, the TB patient population was divided into eight
subgroups based on the absolute number of peripheral
blood lymphocyte. Ranges for categories were chosen as 0–
299, 300–499, 500–699, 700–999, 1000–1199, 1200–1499,
1500–1799, and >1800cells/mm3 (Figure 2(a)). Figure 2(b)
displays the QFT results for patients according to these eight
categories of lymphocyte counts. The proportion of positive
assay results (at a cutoﬀ of 0.35IU/mL) and mitogen-stimu-
lated IFN-γ responses were found to be positively associated
with lymphocyte count (Figures 2(b) and 2(c)). Conversely,
indeterminate assay results showed a negative relationship
with lymphocyte count (Figure 2(b)). Indeterminate result
rates signiﬁcantly increased in the categories with less than4 Tuberculosis Research and Treatment
Table 1: Demographic and baseline clinical characteristics of
pulmonary tuberculosis patients.
Total, n 727
Age, median, range 63 15–97
Female, n, % 208 28.8
Nationality (other than
Japanese), n,% 91 . 2
Sputum smear statusa, n,%
0 167 23.0
1+ 187 25.7
2+ 113 15.5
3+ 252 34.7
unknown 7 1.0
Lung cavitary lesion, n (%) 276 38.0
Underlying preexisting
conditionsb, n,%
Administration of
immunosuppressant before TB
onsetc
39 5.4
Malignant diseases 44 6.1
Serum albumin less than 3.0g/dL 248 34.1
Bedridden 78 10.7
Diabetes mellitus 69 9.5
HIV positive 8 1.1
Liver cirrhosis 5 0.7
Renal failure 5 0.7
History of cerebral infarction 17 2.3
Silicosis 3 0.4
Dementia 45 6.2
Alcoholism 15 2.1
Homeless 34 4.7
Drug abuser 0 0.0
Note. aSmearbysputummicroscopy:0(noacidfastbacilli(AFB)onsmear),
1+ (1–99 AFB per 100 ﬁeld), 2+ (1–10 AFB per ﬁeld), and 3+ (more than 10
AFB per ﬁeld).
bMore than one condition can coexist in the same patient.
cIncluding chronic systemic steroids, antitumor necrosis alpha agents and
immunosuppressive agents.
700cells/mm3. Most markedly, in severe lymphocytopenia
with less than 300cells/mm3, the fraction of test with
indeterminate result was 37.8%.
3.4. Optimum Thresholds in Lymphocyte-Stratiﬁed TB Popu-
lations. Of the 745 employees in our hospital, 357 immuno-
competent individuals had no history of TB disease or
contact with active TB patients, and no prior history of
working in any health care setting (Figure 1). Median age
was 25 years old (range of 21–28). More females (79.3%)
than males participated. None of these subjects had any
immunosuppressive conditions. All healthy subjects had
received BCG vaccination at least once. A positive QFT
result was observed in only 3 participants (0.8%), and there
were no indeterminate results. Median antigen-speciﬁc IFN-
γ response was 0.01IU/mL (interquartile range of 0–0.02).
Using these QFT data from 357 healthy subjects, for the 8
groups of TB patients stratiﬁed by lymphocyte counts as
described above, ROC curve analyses were performed to
determine the optimum cutoﬀ value (Table 3). In the sub-
group with lymphocyte counts of 1800cells/mm3 and over,
the AUROC curve was 0.996 and the appropriate cutoﬀ was
determined to be 0.19IU/mL (sensitivity 96% and speciﬁcity
98%) (Table 3 and Figure 3). A negative trend of AUROC
curve with decreasing lymphocyte counts was observed.
Notably, a sudden decrease in AUROC curve was found in
patients with lymphocytopenia (less than 700cells/mm3).
An appropriate cut-oﬀ for moderate lymphocytopenia (700–
1500cells/mm3) was determined to be 0.1IU/mL. Although
the test performance was considerably decreased in severe
lymphocytopenia group (<700cells/mm3), optimal cutoff
v a l u ew a sf o u n dt ob e0 . 0 4 0I U / m L .
4. Discussion
Diﬀerent interrelated immunomodulatory factors may gen-
erally aﬀect lymphocyte condition in vivo. Malnutrition pre-
disposestoagreaterincidenceofclinicallyapparentinfection
and increased morbidity and mortality due to infection.
Depression of circulating lymphocytes and interleukin-2
productionfollowingmitogenstimulationhasbeenobserved
after a fast of only 7 days [13]. Administration of systemic
corticosteroid may suppress lymphocyte proliferation and
function [14]. T cells from aged animals and humans
consistentlyshowdepressedresponsivenesstomitogens[15].
The presence of a variety of solid tumors is associated with
impaired recall delayed-type hypersensitivity and decreased
in vitro T-cell proliferation to mitogens [16]. Patients
receiving hemodialysis display reduced T-cell function in
vitro, diminished antibody production, and compromised
neutrophil and dendritic cell function [17]. A recent study
has indicated that indeterminate QFT results were increased
in HIV-infected individuals with lower CD4+ Tc e l lc o u n t s
[18, 19]. Persons under these clinical immunosuppressive
conditions may have a high likelihood of developing active
TB disease if they are infected with Mtb. Thus, lympho-
cytopenia or lymphocyte dysfunction is closely associated
with the risk of active TB disease in compromised hosts.
The present study revealed that, in an immunologically uns-
elected population with TB infection, absolute lymphocyte
countsandmitogen-stimulatedIFN-γresponsearepositively
associated with the level of antigen-speciﬁc IFN-γ response
in the whole blood T-cell assay. Because CD4+ T cells are
the major source of IFN-γ in T-cell assay, this ﬁnding
is not unexpected (although our unpublished data using
intracellular cytokine-staining method suggested that CD8+
T cells also produce IFN-γ in some patients). On the other
hand,becausesomepatientswithnormallymphocytecounts
nonetheless had decreased speciﬁc IFN-γ production, other
so far-unidentiﬁed lymphocyte count-independent factors
such as regulatory T-cell eﬀects [20] could explain decreased
IFN-γ responses. Although a poor mitogen response was
rarely observed in patients with normal lymphocyte counts,
good mitogen response could still be mediated in some
patients with severe lymphocytopenia. This may suggest thatTuberculosis Research and Treatment 5
Table 2: Regression coeﬃcients and associated statistics.
Predictors Coeﬃcient SE tP
95% CI
Lower Upper
Age (y) −0.0030 0.0027 −1.12 .26 −0.0083 0.0023
background (IU/mL) 0.57 0.089 6.46 <.0005 0.40 0.75
Mitogen background (IU/mL) 0.016 0.0056 2.78 .006 0.0046 0.027
Albumin (g/dL) 0.0055 0.11 0.05 .96 −0.21 0.22
Hemoglobin (g/dL) −0.023 0.029 −0.79 .43 −0.080 0.034
Neutrophil (1000/mm3) −0.14 0.021 −6.51 <.0005 −0.18 −0.095
Monocyte (1000/mm3) 0.26 0.23 1.13 .26 −0.19 0.72
Lymphocyte (1000/mm3) 0.61 0.13 4.65 <.0005 0.35 0.87
Eosinophil (1000/mm3) −0.63 0.44 −1.43 .15 −1.5 0.23
CRP (mg/dL) −0.015 0.012 −1.27 .21 −0.038 0.0081
AST (IU/L) −0.0023 0.0030 −0.76 .45 −0.0082 0.0036
ALT (IU/L) 0.0047 0.0032 1.48 .14 −0.0015 0.011
Creatinine (mg/dL) 0.18 0.12 1.48 .14 −0.058 0.41
Mitogen × Lymphocyte −0.0073 0.0034 −2.16 .031 −0.014 −0.00067
Intercept (ln IU/mL) 0.22 0.47
Note. Regression coeﬃcients for linear regression of log-transformed antigen-stimulated IFN-γ production by the QuantiFERON-TB Gold. Wald (t)t e s t
statistics are based upon 698 degrees of freedom. P values are not adjusted for multiplicity. Diagnostic plots do not indicate signiﬁcant departures from
normality for the distribution of residuals or nonlinearity in the predictions. The maximum variance inﬂation factor (<4) is within an acceptable range. CRP:
C-reactive protein; AST: aspartate amino transferase; ALT: alanine aminotransferase; SE: standard error; CI: conﬁdence inter.
Table 3: Analysis of area under the receiver operating characteristic curves for lymphocyte-stratiﬁed patients groups.
Lymphocyte
count/mm3 n AUROC curve 95% CI SE
cutoﬀ
value
IU/mL
sensitivity
% 95% CI speciﬁcity
% 95% CI
<300 45 0.86 0.777–0.943 0.04 0.04 80 65.4–90.4 86 81.7–89.2
300–500 57 0.82 0.806–0.938 0.03 0.04 79 66.1–88.6 86 81.7–89.2
500–700 79 0.93a 0.883–0.973 0.02 0.05 89 81.0–95.5 89 85.7–92.4
700–1000 145 0.97b 0.962–0.987 0.01 0.1 87 80.3–91.9 94 91.2–96.3
1000–1200 98 0.98b 0.957–0.994 0.01 0.1 91 83.3–95.7 94 91.2–96.3
1200–1500 121 0.97b 0.954–0.993 0.01 0.1 93 87.4–97.1 95 91.8–96.8
1500–1800 78 0.97b 0.949–0.989 0.01 0.15 91 82.4–96.3 96 93.2–97.6
>1800 104 0.99b 0.992–0.9997 0.002 0.19 96 90.4–98.9 98 96.0–99.2
Note. AUROC: area under the receiver operating characteristic; SE: standard error; CI: Conﬁdence Interval Categories for lymphocyte counts excludet h e
value shown for the upper end of the range.
a: P<. 05 versus <300/mm3 category and P<. 05 versus 300–500/mm3 category.
b: P<. 05 versus <300/mm3 category, P<. 05 versus 300–500/mm3 category, and P<. 05 versus 500–700/mm3 category.
certain leukocytes other than T cells may produce IFN-γ in
responsetowholebloodstimulationbymitogen.Thepresent
study also suggested that neutrophil count was negatively as-
sociated with speciﬁc IFN-γ response. One possibility could
be due to neutrophil-dominant high inﬂammatory status in
advanced tuberculosis with reduced lymphocyte count [21].
Because the risk of LTBI is closely associated with dura-
tion of exposure to and proximity to sputum-smear-positive
pulmonaryTBpatient,TBexposureisusedasasurrogatefor
LTBI. However, as there is no proper gold standard for the
diagnosis of LTBI, one cannot prove the presence or absence
of LTBI [22]. Therefore, for estimating sensitivity and
speciﬁcity of T-cell assay, untreated patients with culture-
positive TB and healthy and low risk individuals without
known exposure to TB have generally been used [23, 24].
However, host immunity would be expected to be
diﬀerent between active TB disease and asymptomatic LTBI.
Recently, Harari et al. showed that dominant TNF-α TB-
speciﬁc CD4+ T-cell response would discriminate between
latent infection and active disease [25]. However, they
excluded patients with immunosuppression (such as HIV+),
malnutrition (body weight < 50kg), and lymphocytepenia
(<3000cells/mm3). TB disease severity is associated with
greater depression of the total lymphocyte and CD4+ T
cell counts. The CD4+ T-cell counts return to normal
levels in most patients after one month of antituberculous
chemotherapy [26]. Active TB attenuates antigen-stimulated
IFN-γ production due to immunosuppression by the disease
process itself and migration of speciﬁc T cells out of the
peripheral blood [27]. This immune suppression in active6 Tuberculosis Research and Treatment
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Figure 2:QuantiFERON-TBGOLDresultsinculture-provenpulmonarytuberculosissubgroupsstratiﬁedbyabsolutenumberofperipheral
blood lymphocyte. (a) Numbers and ages of patients divided into eight subgroups based on peripheral lymphocytes. (b) Proportion of QFT
results with eight subgroups. ∗: P<. 05 versus <300/mm3 category. &: P<. 05 versus <300/mm3 category, P<. 05 versus 300–500/mm3
category, and P<. 05 versus 500–700/mm3 category. #: P<. 05 versus <300/mm3 category, P<. 05 versus 300–500/mm3 category, P<. 05
versus 500–700/mm3 category, and P<. 05 versus 700–1000/mm3 category. $: P<. 05 versus <300/mm3 category, P<. 05 versus 300–
500/mm3 category, P<. 05 versus 500–700/mm3 category, P<. 05 versus 700–1000/mm3 category, and P<. 05 versus 1000–1200/mm3
category. (c) Antigen-stimulated and mitogen-stimulated IFN-γ responses with lymphocyte count (IU/mL). a: Nil (background) IFN-γ
concentration. b:D i ﬀerence between the higher IFN-γ concentration after stimulation with either antigenic peptides ESAT-6 or CFP-10 and
nil (background) IFN-γ concentration. c:D i ﬀerence between the determined IFN-γ concentration after stimulation with mitogen and the
nil (background) IFN-γ concentration.
TB may confound the use of an active TB population as
a surrogate for LTBI. We need to select immunocompetent
healthypersonsknowntohaveTBinfectionasasurrogate,as
far as possible. From the opposite point of view, a population
with active TB disease and associated immunosuppression
could be used as a surrogate for immunosuppressed hosts
with LTBI.
In general, the single cutoﬀ value of 0.35IU/mL as given
in the manufacturer’s instruction is uniformly applied to
the interpretation of the positive result of QFT at present.Tuberculosis Research and Treatment 7
Table 4: Proposed Immunocompetence-stratiﬁed positive criteria and borderline zone for whole blood T-cell assay (QuantiFERON-TB
Gold).
Compromised hosta Immunocompetent host (adult)
≥0.1b <0.1 ≥0.3 0.1–0.3 <0.1
positive Negative postive borderline negative
Note: a: compromised hosts with impaired cell-mediated immunity and lymphocytopenia, such as patients receiving chronic immunosuppressive therapy,
advanced malignant diseases, malnutrition, chronic renal failure on hemodialysis, HIV infection, and hospitalised elderly. b: IU/ml.
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Figure 3: Analysis of area under the receiver operating charac-
teristic curves for lymphocyte-stratiﬁed patients groups. AUROC:
area under the receiver operating characteristic. Error bar; standard
error. ∗: P<. 05 versus <300/mm3 category and P<. 05 versus 300–
500/mm3 category. #: P<. 05 versus <300/mm3 category, P<. 05
versus 300–500/mm3 category, and P<. 05 versus 500–700/mm3
category.
Because QFT is used for evaluating individuals suspected
of having been infected with TB, it is necessary to decide
whether the test result is “positive” or “negative” by using a
single cutoﬀ for clinical decision making. However, because
the test measures antigen-stimulated IFN-γ production from
cells in whole blood, the results are inherently continuous
variables. Interpretation of the test results including conver-
sions and reversions may require comprehension of non-
speciﬁcvariabilityandreproducibilityofthecontinuousdata
[28]. Moreover, speciﬁc IFN-γ production might be aﬀected
by impaired cell-mediated immunity such as in lympho-
cytopenia as described above. Here, using the current
cutoﬀ value of 0.35IU/mL, sensitivity was 89% in popu-
lation with adequate lymphocyte count, whereas in severe
(<700cells/mm3) and moderate (700–1500cells/mm3)l y m -
phocytopenia population, sensitivity ranged from 33% to
75% (Table 3). Antigen-speciﬁc responses and the test per-
formance were markedly attenuated especially in severe lym-
phocytopenia. Thus, immunosuppression with severe lym-
phocytopenia may compromise the test performance.
A recent report indicated that QFT sensitivity using the
0.35IU/mL cutoﬀ in high-incidence settings (69%) might be
lower compared with low-burden countries (83%) probably
due to several factors including HIV coinfection, advanced
disease, and malnutrition [29]. The manufacturer deﬁned
assay cut-oﬀ 0.35IU/mL allows for high speciﬁcity but likely
at some cost in sensitivity, especially under immunosuppres-
sive conditions with lymphocytopenia. Our data suggest that
a cut-oﬀ of 0.2IU/mL might be more appropriate for TB-
infected immunocompetent subjects with normal lympho-
cyte count and low inﬂammatory reaction level which would
be consistent with LTBI. Similarly, a cut-oﬀ of 0.1IU/mL
maximized the sensitivity without loss of speciﬁcity in
moderate lymphocytopenic population. In the low burden
setting, we propose that the test result should be considered
positive if the speciﬁc response is greater than 0.1IU/mL,
especially under immunosuppressive conditions associated
with lymphocytopenia (Table 4).
The cutoﬀ value and deﬁnition of conversion in the T-
cell assays for serial testing is a matter of debate and research
both in high- and low-burden settings [30]. Since there
is likely to be both individual immunological diversity as
well as inherent variability in the determination of IFN-
γ value, it could be relevant to establish a borderline grey
zone [31]. We propose that in immunocompetent healthy
subjects, borderline zone on both sides of the optimal cut-
oﬀ 0.2IU/mL from our analysis would be relevant (i.e., 0.1–
0.3IU/mL) in low endemic country. Any value less than
0.1IU/mL is considered “deﬁnitely negative”, and any value
equal to or greater than 0.3IU/mL is considered “deﬁnitely
positive” (Table 4). In Japan, negative criteria for QFT are
taken as less than 0.1IU/mL at present, and the result of
the test is considered “equivocal” borderline if the response
to the speciﬁc antigens is equal or greater than 0.1 and less
than 0.35IU/mL. In the present long-term study, we used the
QFT assay with two speciﬁc antigens: ESAT-6 and CFP-10.
In the QFT-IT assay, new TB-Antigen 7.7 in addition to the
two conventional antigens has been introduced and might
incrementally improve sensitivity [32, 33]; however, the cut-
oﬀ 0.35IU/mL remains unchanged.
In conclusion, our large longitudinal study revealed that
the absolute number of peripheral blood lymphocyte was
closely associated with antigen-stimulated IFN-γ production
in whole blood assay in unselected TB patients. Criteria for
assigning a positive result should be stratiﬁed to allow for
greater performance depending on the immune status of the
subjects, especially in immunocompromised patients with
impaired cell-mediated immunity who are at increased risk
of progression to active TB disease.8 Tuberculosis Research and Treatment
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